Anvisa é 1ª agência a aprovar novo tratamento para leucemia e linfoma

Anvisa é primeira agência a aprovar novo tratamento para leucemia e linfoma

[{"selector":"#anim-3f058167-f113-4f43-b2fd-afc964a08d6a","keyframes":{"opacity":[0,1]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-4c67589b-0977-4100-9e49-f5ee17c57206","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-80401ada-3379-4b5a-8db6-0904e4a4361f","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-4ea68676-7d30-4a68-b322-8dd01975ccd1","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] FatCamera/GettyImages

[{"selector":"#anim-fe4a0e07-1108-46d7-bec2-09045f7682c5","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-6b429cee-684f-4610-89e6-8eda26776fd9","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-f15c0ad5-619d-49e5-a4b6-42bb542e3bbf","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-85394ec0-6347-4759-9bf4-e56e31e58537","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] A Anvisa foi a primeira agência regulatória no mundo a aprovar o medicamento Jaypirce (pirtobrutinibe), um inibidor da enzima tirosina quinase de Bruton (BTK), da empresa Eli Lilly Estadão COnteúdo

[{"selector":"#anim-085a9484-abce-4279-b7bb-1e4363ba5933","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-e115c354-09df-4e12-93e8-806a6f77dbb0","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-91ba2921-12f0-453c-ba06-5d0cc149e9b0","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-4cfa8b6e-7590-42cc-9407-904b82341550","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-73f4789c-c19c-4054-bf97-36002156e1a4 [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(-23.11656593740653%, 0, 0)","translate3d(0%, 0, 0)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] O remédio foi aprovado para tratamento de pacientes leucemia linfocítica crônica (LLC) e linfoma linfocítico de pequenas células (LLPC) Anna Shvets/Pexels

[{"selector":"#anim-99042cc9-ef36-4053-943d-4ab7b9f3b2b0","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-a2c0b3c4-22dc-4aba-b601-67e49a4a24c7","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-54a8b123-d094-4ea8-874e-8d4d983189ce","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-7a2a7acd-a111-4b88-9523-9dd7a0c29545","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] O remédio seria para tratamento de segunda linha em casos de leucemia resistentes ao tratamento ou que retornam após o fim do tratamento Tima Miroshnichenko/Pexels

[{"selector":"#anim-645805a9-c181-4609-8768-c7e0448d27a7","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-84ded253-1405-43df-b365-806f3d261a69","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c750389b-fe29-431b-ba33-1458b3b67b81","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-fd8cc6f4-c092-4f3b-9165-bed3ea1a8f23","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] A aprovação ocorre após o estudo BRUIN CLL-321, o primeiro estudo clínico randomizado de Fase 3 em LLC já conduzido exclusivamente em pacientes previamente tratados com um inibidor da BTK Anna Shvets/Pexels

[{"selector":"#anim-3dced734-163c-4a53-a183-2218c8edadc4","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ef5d10f9-195e-45d4-aa07-538d1b16bf0e","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-5fe44782-67ab-40e4-881c-9911ecbe895c","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-95396104-ebaa-4949-8af2-86e781bfd632","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-de43acac-8fbc-4675-94ed-db1d4030958c [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(-7.812499744007886%, 0, 0)","translate3d(0%, 0, 0)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] Os resultados demonstraram que o medicamento ofereceu aumento de sobrevida livre de progressão da doença, com mediana de 14 meses, contra 8,7 meses no grupo de controle, além de redução do risco de progressão da doença ou morte de 46% em participantes que utilizaram o medicamento RDNE Stock project/Pexels

[{"selector":"#anim-700bd43f-50e9-4d06-ac23-6e97b690a818","keyframes":{"opacity":[0,1]},"delay":0,"duration":1500,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-23aa97d4-9dac-4cca-bd1e-49acba21ff8c","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-783ea4ae-c8f9-4464-8058-533ec196d7b0","keyframes":{"opacity":[0,1]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] [{"selector":"#anim-b77c6db3-ab78-4bf4-b301-63714bbb10e3","keyframes":{"transform":["scale(0.3333333333333333)","scale(1)"]},"delay":0,"duration":500,"easing":"cubic-bezier(.3,0,.55,1)","fill":"forwards"}] [{"selector":"#anim-1600c835-9fbc-4131-ad8e-a430d9dfbb7e [data-leaf-element=\"true\"]","keyframes":{"transform":["translate3d(31.242669940911505%, 0, 0)","translate3d(0%, 0, 0)"]},"delay":0,"duration":2000,"easing":"cubic-bezier(.3,0,.55,1)","fill":"both"}] O Instituto Nacional de Câncer (Inca) estima que cerca de 11.540 casos de leucemia devem ser diagnosticados no Brasil em 2025, sendo considerado o décimo tipo de câncer mais frequente na população do país (sem considerar tumores de pele não mieloma) Thirdman/Pexels

CNNBRASIL.COM.BR

[{"selector":"#anim-54b8d6a9-e301-45e6-ae80-b7905c65e1f1","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-ea222fdd-4fec-421f-a641-3cadab22e89a","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.4, 0.4, 0.0, 1)","fill":"both"}] [{"selector":"#anim-67a86a38-a94f-4a63-a2ba-af5b233c7c8d","keyframes":{"opacity":[0,1]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-d6a5efe4-739b-4a2c-8bbb-1432575045e0","keyframes":{"transform":["translate3d(0px, 2132.63615%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-253a07c7-c11f-4054-930f-a67edf3c3549","keyframes":{"opacity":[0,1]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-14bcf98b-73bd-45ea-b7c6-65751c67c885","keyframes":{"transform":["translate3d(-117.84387%, 0px, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":600,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-c3628d3f-8785-4f2a-ad27-3f40910dd374","keyframes":{"opacity":[0,1]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] [{"selector":"#anim-9c9454d0-c836-41ca-ad3a-18b140f29bc0","keyframes":{"transform":["translate3d(0px, 870.06218%, 0)","translate3d(0px, 0px, 0)"]},"delay":0,"duration":1000,"easing":"cubic-bezier(0.2, 0.6, 0.0, 1)","fill":"both"}] Freepick leia mais em